nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—CYP3A4—Vandetanib—thyroid cancer	0.1	0.286	CbGbCtD
Ranolazine—CYP2D6—Sorafenib—thyroid cancer	0.0953	0.272	CbGbCtD
Ranolazine—CYP3A4—Sorafenib—thyroid cancer	0.0606	0.173	CbGbCtD
Ranolazine—CYP2D6—Doxorubicin—thyroid cancer	0.0578	0.165	CbGbCtD
Ranolazine—CYP3A4—Doxorubicin—thyroid cancer	0.0368	0.105	CbGbCtD
Ranolazine—Carvedilol—HIF1A—thyroid cancer	0.0148	1	CrCbGaD
Ranolazine—Pain in extremity—Sorafenib—thyroid cancer	0.00486	0.00766	CcSEcCtD
Ranolazine—Visual impairment—Vandetanib—thyroid cancer	0.0048	0.00757	CcSEcCtD
Ranolazine—Eye disorder—Vandetanib—thyroid cancer	0.00466	0.00734	CcSEcCtD
Ranolazine—Cardiac disorder—Vandetanib—thyroid cancer	0.00462	0.00729	CcSEcCtD
Ranolazine—Angiopathy—Vandetanib—thyroid cancer	0.00452	0.00712	CcSEcCtD
Ranolazine—Dehydration—Sorafenib—thyroid cancer	0.00452	0.00712	CcSEcCtD
Ranolazine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00449	0.00708	CcSEcCtD
Ranolazine—Arrhythmia—Vandetanib—thyroid cancer	0.00445	0.00701	CcSEcCtD
Ranolazine—Breast disorder—Sorafenib—thyroid cancer	0.00439	0.00692	CcSEcCtD
Ranolazine—Mental disorder—Vandetanib—thyroid cancer	0.00436	0.00688	CcSEcCtD
Ranolazine—Malnutrition—Vandetanib—thyroid cancer	0.00434	0.00684	CcSEcCtD
Ranolazine—Muscle spasms—Vandetanib—thyroid cancer	0.00417	0.00657	CcSEcCtD
Ranolazine—Pancreatitis—Sorafenib—thyroid cancer	0.00412	0.00649	CcSEcCtD
Ranolazine—Vision blurred—Vandetanib—thyroid cancer	0.00409	0.00644	CcSEcCtD
Ranolazine—Tremor—Vandetanib—thyroid cancer	0.00406	0.0064	CcSEcCtD
Ranolazine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00402	0.00634	CcSEcCtD
Ranolazine—Serum creatinine increased—Epirubicin—thyroid cancer	0.00402	0.00634	CcSEcCtD
Ranolazine—Thrombocytosis—Epirubicin—thyroid cancer	0.00398	0.00627	CcSEcCtD
Ranolazine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00387	0.00609	CcSEcCtD
Ranolazine—Parosmia—Epirubicin—thyroid cancer	0.00381	0.00601	CcSEcCtD
Ranolazine—Loss of consciousness—Vandetanib—thyroid cancer	0.00381	0.00601	CcSEcCtD
Ranolazine—Weight decreased—Sorafenib—thyroid cancer	0.0038	0.00599	CcSEcCtD
Ranolazine—Cough—Vandetanib—thyroid cancer	0.00378	0.00596	CcSEcCtD
Ranolazine—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00372	0.00586	CcSEcCtD
Ranolazine—Thrombocytosis—Doxorubicin—thyroid cancer	0.00368	0.0058	CcSEcCtD
Ranolazine—Renal failure—Sorafenib—thyroid cancer	0.00368	0.0058	CcSEcCtD
Ranolazine—Anxiety—Vandetanib—thyroid cancer	0.00368	0.0058	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00367	0.00578	CcSEcCtD
Ranolazine—Dry mouth—Vandetanib—thyroid cancer	0.00361	0.00569	CcSEcCtD
Ranolazine—Epistaxis—Sorafenib—thyroid cancer	0.00353	0.00557	CcSEcCtD
Ranolazine—Parosmia—Doxorubicin—thyroid cancer	0.00353	0.00556	CcSEcCtD
Ranolazine—Nervous system disorder—Vandetanib—thyroid cancer	0.00347	0.00547	CcSEcCtD
Ranolazine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00347	0.00546	CcSEcCtD
Ranolazine—Skin disorder—Vandetanib—thyroid cancer	0.00344	0.00542	CcSEcCtD
Ranolazine—Dermatitis atopic—Epirubicin—thyroid cancer	0.00334	0.00527	CcSEcCtD
Ranolazine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00332	0.00523	CcSEcCtD
Ranolazine—Connective tissue disorder—Sorafenib—thyroid cancer	0.0033	0.00521	CcSEcCtD
Ranolazine—Urethral disorder—Sorafenib—thyroid cancer	0.00329	0.00519	CcSEcCtD
Ranolazine—Insomnia—Vandetanib—thyroid cancer	0.0032	0.00505	CcSEcCtD
Ranolazine—Paraesthesia—Vandetanib—thyroid cancer	0.00318	0.00501	CcSEcCtD
Ranolazine—Dyspnoea—Vandetanib—thyroid cancer	0.00316	0.00497	CcSEcCtD
Ranolazine—Tinnitus—Sorafenib—thyroid cancer	0.00313	0.00494	CcSEcCtD
Ranolazine—Cardiac disorder—Sorafenib—thyroid cancer	0.00312	0.00492	CcSEcCtD
Ranolazine—Dyspepsia—Vandetanib—thyroid cancer	0.00312	0.00491	CcSEcCtD
Ranolazine—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00309	0.00487	CcSEcCtD
Ranolazine—Decreased appetite—Vandetanib—thyroid cancer	0.00308	0.00485	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00306	0.00482	CcSEcCtD
Ranolazine—Fatigue—Vandetanib—thyroid cancer	0.00305	0.00481	CcSEcCtD
Ranolazine—Angiopathy—Sorafenib—thyroid cancer	0.00305	0.00481	CcSEcCtD
Ranolazine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00303	0.00477	CcSEcCtD
Ranolazine—Constipation—Vandetanib—thyroid cancer	0.00303	0.00477	CcSEcCtD
Ranolazine—Arrhythmia—Sorafenib—thyroid cancer	0.003	0.00473	CcSEcCtD
Ranolazine—Mental disorder—Sorafenib—thyroid cancer	0.00294	0.00464	CcSEcCtD
Ranolazine—Malnutrition—Sorafenib—thyroid cancer	0.00293	0.00461	CcSEcCtD
Ranolazine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00289	0.00456	CcSEcCtD
Ranolazine—Muscle spasms—Sorafenib—thyroid cancer	0.00281	0.00443	CcSEcCtD
Ranolazine—Abdominal pain—Vandetanib—thyroid cancer	0.0028	0.00441	CcSEcCtD
Ranolazine—Angioedema—Sorafenib—thyroid cancer	0.00267	0.00421	CcSEcCtD
Ranolazine—Syncope—Sorafenib—thyroid cancer	0.00262	0.00414	CcSEcCtD
Ranolazine—Leukopenia—Sorafenib—thyroid cancer	0.00262	0.00413	CcSEcCtD
Ranolazine—Creatinine increased—Epirubicin—thyroid cancer	0.0026	0.0041	CcSEcCtD
Ranolazine—Loss of consciousness—Sorafenib—thyroid cancer	0.00257	0.00405	CcSEcCtD
Ranolazine—Cough—Sorafenib—thyroid cancer	0.00255	0.00402	CcSEcCtD
Ranolazine—Asthenia—Vandetanib—thyroid cancer	0.00254	0.004	CcSEcCtD
Ranolazine—Gait disturbance—Epirubicin—thyroid cancer	0.00253	0.00399	CcSEcCtD
Ranolazine—Coordination abnormal—Epirubicin—thyroid cancer	0.00252	0.00397	CcSEcCtD
Ranolazine—Pruritus—Vandetanib—thyroid cancer	0.0025	0.00395	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00247	0.0039	CcSEcCtD
Ranolazine—Dry mouth—Sorafenib—thyroid cancer	0.00244	0.00384	CcSEcCtD
Ranolazine—Creatinine increased—Doxorubicin—thyroid cancer	0.0024	0.00379	CcSEcCtD
Ranolazine—Shock—Sorafenib—thyroid cancer	0.00235	0.0037	CcSEcCtD
Ranolazine—Gait disturbance—Doxorubicin—thyroid cancer	0.00234	0.0037	CcSEcCtD
Ranolazine—Nervous system disorder—Sorafenib—thyroid cancer	0.00234	0.00369	CcSEcCtD
Ranolazine—Dizziness—Vandetanib—thyroid cancer	0.00234	0.00369	CcSEcCtD
Ranolazine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00234	0.00368	CcSEcCtD
Ranolazine—Blood urea increased—Epirubicin—thyroid cancer	0.00233	0.00368	CcSEcCtD
Ranolazine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00233	0.00367	CcSEcCtD
Ranolazine—Skin disorder—Sorafenib—thyroid cancer	0.00232	0.00366	CcSEcCtD
Ranolazine—Anorexia—Sorafenib—thyroid cancer	0.00228	0.00359	CcSEcCtD
Ranolazine—Vomiting—Vandetanib—thyroid cancer	0.00225	0.00355	CcSEcCtD
Ranolazine—Rash—Vandetanib—thyroid cancer	0.00223	0.00352	CcSEcCtD
Ranolazine—Dermatitis—Vandetanib—thyroid cancer	0.00223	0.00351	CcSEcCtD
Ranolazine—Headache—Vandetanib—thyroid cancer	0.00222	0.00349	CcSEcCtD
Ranolazine—Blood urea increased—Doxorubicin—thyroid cancer	0.00216	0.00341	CcSEcCtD
Ranolazine—Dyspnoea—Sorafenib—thyroid cancer	0.00213	0.00336	CcSEcCtD
Ranolazine—Nausea—Vandetanib—thyroid cancer	0.0021	0.00331	CcSEcCtD
Ranolazine—Dyspepsia—Sorafenib—thyroid cancer	0.0021	0.00331	CcSEcCtD
Ranolazine—Decreased appetite—Sorafenib—thyroid cancer	0.00208	0.00327	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00206	0.00325	CcSEcCtD
Ranolazine—Fatigue—Sorafenib—thyroid cancer	0.00206	0.00324	CcSEcCtD
Ranolazine—Constipation—Sorafenib—thyroid cancer	0.00204	0.00322	CcSEcCtD
Ranolazine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00195	0.00308	CcSEcCtD
Ranolazine—Renal failure acute—Epirubicin—thyroid cancer	0.00194	0.00306	CcSEcCtD
Ranolazine—Hot flush—Epirubicin—thyroid cancer	0.00192	0.00302	CcSEcCtD
Ranolazine—Menopausal symptoms—Epirubicin—thyroid cancer	0.0019	0.003	CcSEcCtD
Ranolazine—Urticaria—Sorafenib—thyroid cancer	0.0019	0.00299	CcSEcCtD
Ranolazine—Abdominal pain—Sorafenib—thyroid cancer	0.00189	0.00297	CcSEcCtD
Ranolazine—Lethargy—Epirubicin—thyroid cancer	0.00183	0.00289	CcSEcCtD
Ranolazine—Renal failure acute—Doxorubicin—thyroid cancer	0.0018	0.00284	CcSEcCtD
Ranolazine—Diplopia—Epirubicin—thyroid cancer	0.0018	0.00283	CcSEcCtD
Ranolazine—Pain in extremity—Epirubicin—thyroid cancer	0.0018	0.00283	CcSEcCtD
Ranolazine—Hot flush—Doxorubicin—thyroid cancer	0.00178	0.0028	CcSEcCtD
Ranolazine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00176	0.00277	CcSEcCtD
Ranolazine—Asthenia—Sorafenib—thyroid cancer	0.00171	0.0027	CcSEcCtD
Ranolazine—Lethargy—Doxorubicin—thyroid cancer	0.0017	0.00267	CcSEcCtD
Ranolazine—Pruritus—Sorafenib—thyroid cancer	0.00169	0.00266	CcSEcCtD
Ranolazine—Blood creatinine increased—Epirubicin—thyroid cancer	0.00168	0.00265	CcSEcCtD
Ranolazine—Dehydration—Epirubicin—thyroid cancer	0.00167	0.00263	CcSEcCtD
Ranolazine—Pain in extremity—Doxorubicin—thyroid cancer	0.00166	0.00262	CcSEcCtD
Ranolazine—Diplopia—Doxorubicin—thyroid cancer	0.00166	0.00262	CcSEcCtD
Ranolazine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00164	0.00258	CcSEcCtD
Ranolazine—Breast disorder—Epirubicin—thyroid cancer	0.00162	0.00256	CcSEcCtD
Ranolazine—Dizziness—Sorafenib—thyroid cancer	0.00158	0.00249	CcSEcCtD
Ranolazine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00156	0.00245	CcSEcCtD
Ranolazine—Dehydration—Doxorubicin—thyroid cancer	0.00154	0.00243	CcSEcCtD
Ranolazine—Eosinophilia—Epirubicin—thyroid cancer	0.00154	0.00242	CcSEcCtD
Ranolazine—Pancreatitis—Epirubicin—thyroid cancer	0.00152	0.0024	CcSEcCtD
Ranolazine—Vomiting—Sorafenib—thyroid cancer	0.00152	0.00239	CcSEcCtD
Ranolazine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00152	0.00239	CcSEcCtD
Ranolazine—Rash—Sorafenib—thyroid cancer	0.00151	0.00237	CcSEcCtD
Ranolazine—Dermatitis—Sorafenib—thyroid cancer	0.0015	0.00237	CcSEcCtD
Ranolazine—Breast disorder—Doxorubicin—thyroid cancer	0.0015	0.00237	CcSEcCtD
Ranolazine—Headache—Sorafenib—thyroid cancer	0.0015	0.00236	CcSEcCtD
Ranolazine—Pancytopenia—Epirubicin—thyroid cancer	0.00147	0.00232	CcSEcCtD
Ranolazine—Dysuria—Epirubicin—thyroid cancer	0.00145	0.00229	CcSEcCtD
Ranolazine—Eosinophilia—Doxorubicin—thyroid cancer	0.00142	0.00224	CcSEcCtD
Ranolazine—Nausea—Sorafenib—thyroid cancer	0.00142	0.00224	CcSEcCtD
Ranolazine—Pancreatitis—Doxorubicin—thyroid cancer	0.00141	0.00222	CcSEcCtD
Ranolazine—Weight decreased—Epirubicin—thyroid cancer	0.0014	0.00221	CcSEcCtD
Ranolazine—Pancytopenia—Doxorubicin—thyroid cancer	0.00136	0.00215	CcSEcCtD
Ranolazine—Renal failure—Epirubicin—thyroid cancer	0.00136	0.00214	CcSEcCtD
Ranolazine—Dysuria—Doxorubicin—thyroid cancer	0.00134	0.00212	CcSEcCtD
Ranolazine—Haematuria—Epirubicin—thyroid cancer	0.00132	0.00208	CcSEcCtD
Ranolazine—Epistaxis—Epirubicin—thyroid cancer	0.0013	0.00206	CcSEcCtD
Ranolazine—Weight decreased—Doxorubicin—thyroid cancer	0.0013	0.00205	CcSEcCtD
Ranolazine—Bradycardia—Epirubicin—thyroid cancer	0.00126	0.00199	CcSEcCtD
Ranolazine—Renal failure—Doxorubicin—thyroid cancer	0.00126	0.00198	CcSEcCtD
Ranolazine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00124	0.00195	CcSEcCtD
Ranolazine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00123	0.00193	CcSEcCtD
Ranolazine—Oedema peripheral—Epirubicin—thyroid cancer	0.00122	0.00193	CcSEcCtD
Ranolazine—Haematuria—Doxorubicin—thyroid cancer	0.00122	0.00192	CcSEcCtD
Ranolazine—Connective tissue disorder—Epirubicin—thyroid cancer	0.00122	0.00192	CcSEcCtD
Ranolazine—Urethral disorder—Epirubicin—thyroid cancer	0.00122	0.00192	CcSEcCtD
Ranolazine—Epistaxis—Doxorubicin—thyroid cancer	0.00121	0.0019	CcSEcCtD
Ranolazine—Visual impairment—Epirubicin—thyroid cancer	0.0012	0.00189	CcSEcCtD
Ranolazine—Bradycardia—Doxorubicin—thyroid cancer	0.00117	0.00184	CcSEcCtD
Ranolazine—Eye disorder—Epirubicin—thyroid cancer	0.00116	0.00183	CcSEcCtD
Ranolazine—Tinnitus—Epirubicin—thyroid cancer	0.00116	0.00183	CcSEcCtD
Ranolazine—Cardiac disorder—Epirubicin—thyroid cancer	0.00115	0.00182	CcSEcCtD
Ranolazine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00114	0.0018	CcSEcCtD
Ranolazine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00113	0.00179	CcSEcCtD
Ranolazine—Oedema peripheral—Doxorubicin—thyroid cancer	0.00113	0.00178	CcSEcCtD
Ranolazine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00113	0.00178	CcSEcCtD
Ranolazine—Angiopathy—Epirubicin—thyroid cancer	0.00113	0.00178	CcSEcCtD
Ranolazine—Urethral disorder—Doxorubicin—thyroid cancer	0.00113	0.00178	CcSEcCtD
Ranolazine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00112	0.00176	CcSEcCtD
Ranolazine—Arrhythmia—Epirubicin—thyroid cancer	0.00111	0.00175	CcSEcCtD
Ranolazine—Visual impairment—Doxorubicin—thyroid cancer	0.00111	0.00175	CcSEcCtD
Ranolazine—Mental disorder—Epirubicin—thyroid cancer	0.00109	0.00172	CcSEcCtD
Ranolazine—Malnutrition—Epirubicin—thyroid cancer	0.00108	0.0017	CcSEcCtD
Ranolazine—Eye disorder—Doxorubicin—thyroid cancer	0.00107	0.00169	CcSEcCtD
Ranolazine—Tinnitus—Doxorubicin—thyroid cancer	0.00107	0.00169	CcSEcCtD
Ranolazine—Cardiac disorder—Doxorubicin—thyroid cancer	0.00107	0.00168	CcSEcCtD
Ranolazine—Flatulence—Epirubicin—thyroid cancer	0.00107	0.00168	CcSEcCtD
Ranolazine—Angiopathy—Doxorubicin—thyroid cancer	0.00104	0.00164	CcSEcCtD
Ranolazine—Muscle spasms—Epirubicin—thyroid cancer	0.00104	0.00164	CcSEcCtD
Ranolazine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00104	0.00163	CcSEcCtD
Ranolazine—Arrhythmia—Doxorubicin—thyroid cancer	0.00103	0.00162	CcSEcCtD
Ranolazine—Vision blurred—Epirubicin—thyroid cancer	0.00102	0.00161	CcSEcCtD
Ranolazine—Mental disorder—Doxorubicin—thyroid cancer	0.00101	0.00159	CcSEcCtD
Ranolazine—Malnutrition—Doxorubicin—thyroid cancer	0.001	0.00158	CcSEcCtD
Ranolazine—Flatulence—Doxorubicin—thyroid cancer	0.000986	0.00155	CcSEcCtD
Ranolazine—Vertigo—Epirubicin—thyroid cancer	0.000971	0.00153	CcSEcCtD
Ranolazine—Syncope—Epirubicin—thyroid cancer	0.000969	0.00153	CcSEcCtD
Ranolazine—Leukopenia—Epirubicin—thyroid cancer	0.000968	0.00153	CcSEcCtD
Ranolazine—Muscle spasms—Doxorubicin—thyroid cancer	0.000962	0.00152	CcSEcCtD
Ranolazine—Palpitations—Epirubicin—thyroid cancer	0.000955	0.00151	CcSEcCtD
Ranolazine—Loss of consciousness—Epirubicin—thyroid cancer	0.00095	0.0015	CcSEcCtD
Ranolazine—Cough—Epirubicin—thyroid cancer	0.000943	0.00149	CcSEcCtD
Ranolazine—Vision blurred—Doxorubicin—thyroid cancer	0.000943	0.00149	CcSEcCtD
Ranolazine—Anxiety—Epirubicin—thyroid cancer	0.000917	0.00145	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000914	0.00144	CcSEcCtD
Ranolazine—Dry mouth—Epirubicin—thyroid cancer	0.0009	0.00142	CcSEcCtD
Ranolazine—Vertigo—Doxorubicin—thyroid cancer	0.000899	0.00142	CcSEcCtD
Ranolazine—Syncope—Doxorubicin—thyroid cancer	0.000897	0.00141	CcSEcCtD
Ranolazine—Leukopenia—Doxorubicin—thyroid cancer	0.000895	0.00141	CcSEcCtD
Ranolazine—Confusional state—Epirubicin—thyroid cancer	0.00089	0.0014	CcSEcCtD
Ranolazine—Palpitations—Doxorubicin—thyroid cancer	0.000884	0.00139	CcSEcCtD
Ranolazine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000879	0.00139	CcSEcCtD
Ranolazine—Cough—Doxorubicin—thyroid cancer	0.000873	0.00138	CcSEcCtD
Ranolazine—Shock—Epirubicin—thyroid cancer	0.000868	0.00137	CcSEcCtD
Ranolazine—Nervous system disorder—Epirubicin—thyroid cancer	0.000865	0.00136	CcSEcCtD
Ranolazine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000864	0.00136	CcSEcCtD
Ranolazine—Skin disorder—Epirubicin—thyroid cancer	0.000857	0.00135	CcSEcCtD
Ranolazine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000853	0.00134	CcSEcCtD
Ranolazine—Anxiety—Doxorubicin—thyroid cancer	0.000849	0.00134	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000846	0.00133	CcSEcCtD
Ranolazine—Anorexia—Epirubicin—thyroid cancer	0.000841	0.00133	CcSEcCtD
Ranolazine—Dry mouth—Doxorubicin—thyroid cancer	0.000833	0.00131	CcSEcCtD
Ranolazine—Hypotension—Epirubicin—thyroid cancer	0.000824	0.0013	CcSEcCtD
Ranolazine—Confusional state—Doxorubicin—thyroid cancer	0.000823	0.0013	CcSEcCtD
Ranolazine—Shock—Doxorubicin—thyroid cancer	0.000803	0.00127	CcSEcCtD
Ranolazine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000801	0.00126	CcSEcCtD
Ranolazine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000799	0.00126	CcSEcCtD
Ranolazine—Insomnia—Epirubicin—thyroid cancer	0.000798	0.00126	CcSEcCtD
Ranolazine—Skin disorder—Doxorubicin—thyroid cancer	0.000793	0.00125	CcSEcCtD
Ranolazine—Paraesthesia—Epirubicin—thyroid cancer	0.000792	0.00125	CcSEcCtD
Ranolazine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000789	0.00124	CcSEcCtD
Ranolazine—Dyspnoea—Epirubicin—thyroid cancer	0.000787	0.00124	CcSEcCtD
Ranolazine—Somnolence—Epirubicin—thyroid cancer	0.000784	0.00124	CcSEcCtD
Ranolazine—Anorexia—Doxorubicin—thyroid cancer	0.000778	0.00123	CcSEcCtD
Ranolazine—Dyspepsia—Epirubicin—thyroid cancer	0.000777	0.00122	CcSEcCtD
Ranolazine—Decreased appetite—Epirubicin—thyroid cancer	0.000767	0.00121	CcSEcCtD
Ranolazine—Hypotension—Doxorubicin—thyroid cancer	0.000763	0.0012	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000762	0.0012	CcSEcCtD
Ranolazine—Fatigue—Epirubicin—thyroid cancer	0.000761	0.0012	CcSEcCtD
Ranolazine—Constipation—Epirubicin—thyroid cancer	0.000754	0.00119	CcSEcCtD
Ranolazine—Insomnia—Doxorubicin—thyroid cancer	0.000738	0.00116	CcSEcCtD
Ranolazine—Paraesthesia—Doxorubicin—thyroid cancer	0.000733	0.00116	CcSEcCtD
Ranolazine—Dyspnoea—Doxorubicin—thyroid cancer	0.000728	0.00115	CcSEcCtD
Ranolazine—Feeling abnormal—Epirubicin—thyroid cancer	0.000727	0.00115	CcSEcCtD
Ranolazine—Somnolence—Doxorubicin—thyroid cancer	0.000726	0.00114	CcSEcCtD
Ranolazine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000721	0.00114	CcSEcCtD
Ranolazine—Dyspepsia—Doxorubicin—thyroid cancer	0.000719	0.00113	CcSEcCtD
Ranolazine—Decreased appetite—Doxorubicin—thyroid cancer	0.00071	0.00112	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000705	0.00111	CcSEcCtD
Ranolazine—Fatigue—Doxorubicin—thyroid cancer	0.000704	0.00111	CcSEcCtD
Ranolazine—Urticaria—Epirubicin—thyroid cancer	0.000701	0.0011	CcSEcCtD
Ranolazine—Constipation—Doxorubicin—thyroid cancer	0.000698	0.0011	CcSEcCtD
Ranolazine—Abdominal pain—Epirubicin—thyroid cancer	0.000697	0.0011	CcSEcCtD
Ranolazine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000673	0.00106	CcSEcCtD
Ranolazine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000668	0.00105	CcSEcCtD
Ranolazine—Urticaria—Doxorubicin—thyroid cancer	0.000649	0.00102	CcSEcCtD
Ranolazine—Abdominal pain—Doxorubicin—thyroid cancer	0.000645	0.00102	CcSEcCtD
Ranolazine—Asthenia—Epirubicin—thyroid cancer	0.000633	0.000998	CcSEcCtD
Ranolazine—Pruritus—Epirubicin—thyroid cancer	0.000624	0.000984	CcSEcCtD
Ranolazine—Asthenia—Doxorubicin—thyroid cancer	0.000586	0.000923	CcSEcCtD
Ranolazine—Dizziness—Epirubicin—thyroid cancer	0.000583	0.00092	CcSEcCtD
Ranolazine—Pruritus—Doxorubicin—thyroid cancer	0.000578	0.00091	CcSEcCtD
Ranolazine—Vomiting—Epirubicin—thyroid cancer	0.000561	0.000884	CcSEcCtD
Ranolazine—Rash—Epirubicin—thyroid cancer	0.000556	0.000877	CcSEcCtD
Ranolazine—Dermatitis—Epirubicin—thyroid cancer	0.000556	0.000876	CcSEcCtD
Ranolazine—Headache—Epirubicin—thyroid cancer	0.000553	0.000871	CcSEcCtD
Ranolazine—Dizziness—Doxorubicin—thyroid cancer	0.00054	0.000851	CcSEcCtD
Ranolazine—Nausea—Epirubicin—thyroid cancer	0.000524	0.000826	CcSEcCtD
Ranolazine—Vomiting—Doxorubicin—thyroid cancer	0.000519	0.000818	CcSEcCtD
Ranolazine—Rash—Doxorubicin—thyroid cancer	0.000515	0.000811	CcSEcCtD
Ranolazine—Dermatitis—Doxorubicin—thyroid cancer	0.000514	0.000811	CcSEcCtD
Ranolazine—Headache—Doxorubicin—thyroid cancer	0.000511	0.000806	CcSEcCtD
Ranolazine—Nausea—Doxorubicin—thyroid cancer	0.000485	0.000764	CcSEcCtD
